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A B S T R A C T
Polycystic ovary syndrome (PCOS) affects around 10% of women of reproductive age and is most common in developed countries. The aetiology of PCOS is not
completely understood. Current evidence suggests that the syndrome results from a genetic predisposition interacting with developmental events during fetal or
perinatal life that together increase susceptibility in some individuals. This implies that environmental factors influence the initiation of PCOS in the fetus or infant,
either directly or via the mother. PCOS is often considered to be an ancient disorder but there is no direct proof of this in the medical or historic record. One of the
cardinal features, polycystic ovaries, was first described only in the early 1900s, despite reports of many thousands of autopsies recorded earlier. This conundrum
could be explained by postulating that polycystic ovaries were rare before the 1900s and have become more common over the last 100 years. The hypothesis that
PCOS is a syndrome of the 20th Century would eliminate the need to explain the paradox of why there exists a genetic predisposition to subfertility syndrome.
Introduction
Despite its common occurrence and substantial co-morbidities, in-
cluding type 2 diabetes and obesity, polycystic ovary syndrome (PCOS)
is very poorly understood. Research effort to define the pathophysio-
logical origins of PCOS is urgently needed. There are a number of sci-
entific conundrums surrounding PCOS including its developmental
origins and aetiology that have hampered progress and provoked de-
bate in recent years. Here, we discuss these and present a counter
concept suggesting that PCOS is a syndrome that has emerged to be-
come a more frequent event in the 20th Century. If this postulate is
true, there are major implications for how we investigate the patho-
physiological mechanisms and aetiology of PCOS and its co-morbid-
ities. A better understanding of how environmental factors and genetics
interact, and the nature of the critical environmental exposures, is re-
quired to develop effective syndrome-specific interventions and treat-
ments.
What is polycystic ovary syndrome?
The name ‘PCOS’ focuses on just one diagnostic feature – polycystic
ovarian morphology – which is a misleading description of the ovarian
features [1]. Women with PCOS often believe they have multiple
ovarian cysts based on the name of the condition. However, the ‘cysts’
are actually egg-containing follicles that arrest during follicular growth
[3]. While polycystic ovaries have an elevated number of follicles and
more stromal tissue containing more collagen [2], this is only one di-
agnostic feature of the syndrome of PCOS. Note that in this article we
critically distinguish the discussion between the syndrome of PCOS, and
the clinical feature of polycystic ovaries.
The majority of women with PCOS have elevated androgen levels
due in large part to the increased number of antral follicles containing
thecal cells that hypersecrete androgens [3]. They therefore exhibit
symptoms of excess androgen (hirsutism, acne, central adiposity) and
not only experience infertility (menstrual irregularity, anovulatory in-
fertility, miscarriage) but also have substantially increased risk of be-
coming obese, insulin resistant and of developing type 2 diabetes, non-
alcoholic fatty liver disease, dyslipidaemia and depression [4]. Women
with PCOS have at least a four-fold increased risk of type 2 diabetes,
even without taking into account their additional predisposition to
becoming overweight [5,6]. Thus PCOS can be considered a syndrome
where hormonal underpinnings cause both reproductive and metabolic
features.
Diagnostic criteria for PCOS have evolved following meetings of
experts in 1990 hosted by the NIH [1], in 2003 in Rotterdam [7] and
subsequently by the Androgen Excess Polycystic Ovary Syndrome So-
ciety [8]. Evidence-based guidelines for diagnosis and treatment have
been developed [9,10] and focus on the combination of key features
including oligo or amenorrhea, evidence of androgen excess and poly-
cystic ovarian morphology.
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What are polycystic ovaries?
Polycystic ovaries exhibit several features that include multiple
growth-arrested follicles, an extremely thickened ovarian capsule or
tunica albuginea, and an increased amount of ovarian cortex with
elevated collagen content [2], suggesting a more fibrous composition.
Surprisingly polycystic ovaries were only first described in 1928 by
Lesnoy [11] and by Stein and Leventhal in 1935 [12]. The original
publication by Lesnoy [11] was published in Russian. An English
translation and a copy of the original article are provided in the
Supplementary Information. Both studies describe the hallmark fea-
tures of polycystic ovaries. Interestingly both studies describe utilising
wedge resection as a treatment. Remarkably, variations on this treat-
ment are still sometimes used for treatment of infertility of women with
PCOS [13].
A recent community-based PCOS-prevalence study was conducted
on 728 women born in Adelaide, Australia with an average age of
30 years [14]. Of these women, 277 were selected for further ex-
amination of PCOS symptoms. Amongst these, 108 had transvaginal
ultrasound and the presence of polycystic ovarian morphology was
identified in 41 of these women [(41÷ 108)×277]÷728=0.144].
Thus it was found that 14.4% had polycystic ovaries. A prevalence es-
timate of polycystic ovaries was 17.6% in another study in Turkey [15].
An earlier study in women randomly selected from the electoral roll in
New Zealand with an average age of 33 years found the prevalence of
polycystic ovaries to be 21% (39 out of 183 women diagnosed by ul-
trasound) [16]. Consistent with this, a UK study identified polycystic
ovaries in 23% of women [17]. It should be noted that the prevalence is
age dependent, with a lower incidence of polycystic ovaries in older
women [18].
Are polycystic ovaries a recent clinical entity?
The high current prevalence of polycystic ovaries in Western po-
pulations raises the question of why polycystic ovaries were only first
recognised in the early 1900s [11,12]. Quotes from a number of earlier
publications allude to symptoms in women that could be due to the
syndrome of PCOS [19,20], but these symptoms could also be due to
other causes. We contend that the prevalence of polycystic ovaries is
particularly relevant to estimating the historic incidence of PCOS, since,
although this feature alone does not satisfy current clinical definitions
of PCOS, it is a feature most commonly associated with PCOS and less
likely with other conditions.
If PCOS existed in the early 1900s at the same prevalence it does
today, it is difficult to explain why polycystic ovaries were not de-
scribed much earlier. A few possibilities could explain this. First and
most obviously, polycystic ovaries are now readily diagnosed by ul-
trasonography, and this technology was not commonly available until
the 1960’s. However, polycystic ovaries are easy to identify on lapar-
otomy or autopsy by mere visual observations as they are larger, full of
follicles and fibrous [2]. Another possibility is that autopsies were un-
common prior to the early 1900s. On the contrary, human autopsies
have been conducted at least since the time of Galen (130–216). One
famous Bohemian pathologist Rojitansky (1804–1878) was reported to
have conducted 30,000 autopsies [21] and he described his opportu-
nities to examine ovaries as ‘very extensive’ [22]. King and Meeham
[21] writing on the history of autopsies state that ‘In the sixteenth and
seventeenth centuries very many autopsies were performed and recorded.
One of the great medical compilations of all time is the Sepulchretum of
Theophilus Bonetus (1620–1689), first published in 1679. The second
edition, cited herein, appeared in 1700, in three folio volumes. These vo-
lumes collect over 3000 autopsies, reported in varying length from a few
lines to half a folio page or sometimes more. Some 450 authors are re-
presented, ranging from Galen to the physicians of the late seventeenth
century. All the outstanding physicians of historic note are included – Bar-
tholin, Fallopius, Fernel, Harvey, van Helmont, Malpighi, Paracelsus, Pare,
the Riolans, Sennert, Vesalius, Wepfer and Willis, to name but a few.’ Later
with the development of modern hospitals and the increasing use of
histology, autopsies became common-place. Bichat (1771–1802), who
is regarded as the ‘Father of Histology’, was reported to have conducted
600 autopsies in one year alone [21]. So why is it that polycystic
ovaries were not described prior to the early 1900s?
Some explanations could invoke a predominance of male over fe-
male autopsies, or failure to examine female reproductive tissues, but
these are not tenable. There are regular reports of female autopsy on the
historic record, and these often report irregularities of female re-
productive tissues and organs [23]. Also historically, autopsy patients
were more likely to be of people of reproductive age because lifespans
were shorter than today. Moreover, given that polycystic ovaries are
clearly evident and visible to the naked eye [2], it seems unlikely that
experienced physicians would overlook this irregularity.
With so many opportunities to record the presence of polycystic
ovaries at autopsy over centuries before their first description in the
1900s, it is reasonable to conclude that polycystic ovaries were pre-
viously so rare as to not have been documented. Certainly, the sentinel
publications by Lesnoy and Stein and Leventhal give no indication that
this ovarian morphology was previously known to the medical litera-
ture. Stein and Leventhal clearly believed they were describing a new
entity when they said ‘According to the same authoritative works, little
or no mention is made of bilateral polycystic ovaries accompanied by
amenorrhea….’ [12]. We suggest the possibility that polycystic ovaries
were so rare before the 1900s as to be only first described adequately in
the early 1900s, in which case PCOS is a syndrome that arose largely in
the 20th Century.
Current issues on the genetic origins of PCOS
Currently the cause(s) and aetiology of PCOS are not known. Early
studies of PCOS found familial linkage and subsequent twin studies
identified a sizable genetic component to the heritability of PCOS [24].
GWAS and microsatellite linkage studies have identified a number of
loci associated with PCOS [25]. The genes closest to loci identified as
predisposing to PCOS include FBN3, DENND1A, LHCGR, THADA,
C9orf3, FSHR, HMGA2, INSR, RAB5B, SUMO1P1, TOX3, YAP1, ERBB4,
FSHB, GATA4, KRR1 and RAD50 [see review [26]]. The prospect of
genetic causes of PCOS has triggered much discussion about how genes
leading to reduced fertility could be maintained within a population
[27–31]. Rationally they would normally be eliminated by natural se-
lection unless they confer other advantages to survival of the offspring.
However, none of the genetic loci identified confer an obvious survival
advantage.
As noted earlier, PCOS has been suggested to be an ancient syn-
drome [19,20,27,31]. If this were the case, an alternative explanation
for PCOS susceptibility genes surviving at low frequency in a popula-
tion might be that they confer an attribute to provide a survival ad-
vantage under specific environmental conditions, and that these con-
ditions have since changed to cause the emergence of PCOS as a
common phenotype. In this view, the long term evolution of phenotypic
stability under constant environmental conditions, referred to as ca-
nalisation, could have been disrupted, permitting the expression of
underlying cryptic genetic variation from natural selection or mutation
[32]. As a consequence, PCOS may be viewed as a conditional pheno-
type whereby a specific set of environmental conditions has unmasked a
normally unexpressed genetic pathway, which may provide a survival
advantage under certain conditions, but which offers no advantage and
possibly a serious disadvantage in prevailing conditions.
We have considered an alternative explanation for how genes as-
sociated with a subfertility syndrome such as PCOS persist in a popu-
lation, namely that if the current high prevalence of polycystic ovaries
and PCOS has only just emerged just over 4 generations ago in the
1900s, then there has been very little time for negative selection to
occur.
R.J. Rodgers et al. Medical Hypotheses 124 (2019) 31–34
32
Environmental and fetal origins of PCOS
There is also evidence of a fetal epigenetic origin [33–35] of de-
veloping a predisposition to PCOS, and the challenge is to define a
pathophysiological mechanism that accommodates a contribution of
both genetic and environmental determinants. A fetal or perinatal
origin implies the action of environmental influences [36,37], but the
nature of these factors and their target genes and tissues are unknown.
Many new industrial processes, dietary constituents, food preservation
and cooking methods, and new environmental chemicals, toxins and
drugs have emerged and permeated human culture since then. Any one
of these, alone or in combination, might be a candidate causal agent –
and several have features, biological actions and exposure patterns that
warrant investigation.
It is interesting to note that many other non-communicable meta-
bolic diseases with epigenetic origins are known to be increasing in
prevalence as a result of modern lifestyle factors and environmental
insults affecting fetal and infant development [38–40]. Many of these
agents impact susceptibility to disease later in life through common
pathways, notably as endocrine disrupting chemicals [41], or as pro-
inflammatory insults that alter the microbiome and immune function
[42]. It is possible that environmental factors contributing to PCOS
susceptibility overlap with those contributing to obesity and metabolic
disorder, but complete congruency seems unlikely, as PCOS often pre-
cedes and can occur independently of overweight and obesity [43].
Implications of PCOS as a 20th Century phenomenon
One might assume that epidemiological research methodology will
allow systematic identification of candidate causal agents, but the
complexity of establishing cause-and-effect relationships is challenging.
For example, many decades of work were required to identify tobacco
smoking as responsible for the epidemic of lung cancer arising in the
1920s, amongst the list of other possible candidates including ‘asphalt
dust from newly tarred roads, industrial air pollution and latent effects
from exposure to poison gas in the First World War or the global in-
fluenza pandemic’ [44]. Identifying an environmental cause of PCOS
would be particularly difficult if the effector(s) is operating at a specific
stage of fetal or infant development.
In conclusion, we urge researchers investigating the origins and
aetiology of PCOS and its co-morbidities to consider at least the pro-
spect of a relatively recent, environmental cause(s) of PCOS. To in-
vestigate this hypothesis we suggest a multi-disciplinary strategy to
identify links between candidate environmental agents and PCOS in-
cidence, to develop useful experimental models that allow evaluation of
causal triggers and mechanisms, and a focus on research that in-
vestigates biologically plausible pathways linking the known fetal and
neonatal developmental changes with the adult manifestation of the
syndrome. Only when these pieces of the puzzle are in place will we be
in a position to devise public health approaches and associated inter-
ventions to protect future generations from PCOS.
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